Unknown

Dataset Information

0

Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementia.


ABSTRACT: BACKGROUND: Infection with HIV-1 may result in severe cognitive and motor impairment, referred to as HIV-1-associated dementia (HAD). While its prevalence has dropped significantly in the era of combination antiretroviral therapy, milder neurocognitive disorders persist with a high prevalence. To identify additional therapeutic targets for treating HIV-associated neurocognitive disorders, several candidate gene polymorphisms have been evaluated, but few have been replicated across multiple studies. METHODS: We here tested 7 candidate gene polymorphisms for association with HAD in a case-control study consisting of 86 HAD cases and 246 non-HAD AIDS patients as controls. Since infected monocytes and macrophages are thought to play an important role in the infection of the brain, 5 recently identified single nucleotide polymorphisms (SNPs) affecting HIV-1 replication in macrophages in vitro were also tested. RESULTS: The CCR5 wt/?32 genotype was only associated with HAD in individuals who developed AIDS prior to 1991, in agreement with the observed fading effect of this genotype on viral load set point. A significant difference in genotype distribution among all cases and controls irrespective of year of AIDS diagnosis was found only for a SNP in candidate gene PREP1 (p = 1.2 × 10(-5)). Prep1 has recently been identified as a transcription factor preferentially binding the -2,518 G allele in the promoter of the gene encoding MCP-1, a protein with a well established role in the etiology of HAD. CONCLUSION: These results support previous findings suggesting an important role for MCP-1 in the onset of HIV-1-associated neurocognitive disorders.

SUBMITTER: Bol SM 

PROVIDER: S-EPMC3274517 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Infection with HIV-1 may result in severe cognitive and motor impairment, referred to as HIV-1-associated dementia (HAD). While its prevalence has dropped significantly in the era of combination antiretroviral therapy, milder neurocognitive disorders persist with a high prevalence. To identify additional therapeutic targets for treating HIV-associated neurocognitive disorders, several candidate gene polymorphisms have been evaluated, but few have been replicated across multipl  ...[more]

Similar Datasets

| S-EPMC7002124 | biostudies-literature
| S-EPMC1216068 | biostudies-literature
| S-EPMC8687305 | biostudies-literature
| S-EPMC7846141 | biostudies-literature
| S-EPMC3415858 | biostudies-literature
2010-06-24 | E-GEOD-4227 | biostudies-arrayexpress
2013-11-08 | E-GEOD-52155 | biostudies-arrayexpress
| S-EPMC4741865 | biostudies-literature
| 2135070 | ecrin-mdr-crc
2020-02-24 | GSE111333 | GEO